Literature DB >> 1953780

Long-lasting vasoconstriction and efficient regional extraction of endothelin-1 in human splanchnic and renal tissues.

E Weitzberg1, G Ahlborg, J M Lundberg.   

Abstract

Six healthy subjects were given endothelin-1, intravenously in a dose of 4 pmol.kg-1.min-1 for 20 min. Blood samples were drawn from arterial, hepatic and renal vein catheters for determinations of splanchnic and renal blood flows and the extraction of endothelin-1 in these vascular beds. Intravenous infusion of endothelin-1 increased the mean arterial blood pressure by 6.8 +/- 2.0 mm Hg (p less than 0.05) and reduced splanchnic and renal blood flows by 34% (p less than 0.005) and 26% (p less than 0.001) respectively. Return to basal flow values occurred after about 1 hr for the splanchnic and 3 hrs for the renal blood flow. The fractional extractions of endothelin-1-like immunoreactivity corresponded to 75 +/- 2% and 60 +/- 2% in the splanchnic and renal vascular beds, respectively. The disappearance curve in plasma and two half-lives of 1.4 +/- 0.1 min and 35 +/- 2.8 min respectively.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1953780     DOI: 10.1016/s0006-291x(05)81336-1

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  13 in total

1.  [125I]-PD151242: a selective ligand for endothelin ETA receptors in human kidney which localizes to renal vasculature.

Authors:  A P Davenport; R E Kuc; S L Hoskins; F E Karet; F Fitzgerald
Journal:  Br J Pharmacol       Date:  1994-12       Impact factor: 8.739

Review 2.  Endothelial modification of pulmonary vascular tone.

Authors:  N P Curzen; K B Jourdan; J A Mitchell
Journal:  Intensive Care Med       Date:  1996-06       Impact factor: 17.440

3.  The increase in human plasma immunoreactive endothelin but not big endothelin-1 or its C-terminal fragment induced by systemic administration of the endothelin antagonist TAK-044.

Authors:  C Plumpton; C J Ferro; W G Haynes; D J Webb; A P Davenport
Journal:  Br J Pharmacol       Date:  1996-09       Impact factor: 8.739

Review 4.  The emerging role of endothelin-1 in the pathogenesis of pre-eclampsia.

Authors:  Langeza Saleh; Koen Verdonk; Willy Visser; Anton H van den Meiracker; A H Jan Danser
Journal:  Ther Adv Cardiovasc Dis       Date:  2016-01-10

5.  Bosentan-improved cardiopulmonary vascular performance and increased plasma levels of endothelin-1 in porcine endotoxin shock.

Authors:  E Weitzberg; A Hemsén; A Rudehill; A Modin; M Wanecek; J M Lundberg
Journal:  Br J Pharmacol       Date:  1996-06       Impact factor: 8.739

Review 6.  Is urotensin-II the new endothelin?

Authors:  Janet J Maguire; Anthony P Davenport
Journal:  Br J Pharmacol       Date:  2002-11       Impact factor: 8.739

7.  Plasma C-terminal pro-endothelin-1 is associated with left ventricular mass index and aortic root diameter in African-American adults with hypertension.

Authors:  M A Al-Omari; M Khaleghi; T H Mosley; N G Morgenthaler; J Struck; A Bergmann; I J Kullo
Journal:  J Hum Hypertens       Date:  2010-02-25       Impact factor: 3.012

8.  Coingestion of cyclooxygenase inhibitors can worsen severe paracetamol poisoning by middle-sized and small arteries vasoconstriction.

Authors:  Francis Schneider; Agnès Neuville; Ferhat Meziani; Carole Meyer; Parissa Assemi; Thierry Lavigne; Vincent Castelain
Journal:  Intensive Care Med       Date:  2003-09-26       Impact factor: 17.440

9.  Phosphoramidon inhibition of the in vivo conversion of big endothelin-1 to endothelin-1 in the human forearm.

Authors:  C Plumpton; W G Haynes; D J Webb; A P Davenport
Journal:  Br J Pharmacol       Date:  1995-09       Impact factor: 8.739

10.  The endothelin receptor antagonist bosentan restores gut oxygen delivery and reverses intestinal mucosal acidosis in porcine endotoxin shock.

Authors:  A Oldner; M Wanecek; M Goiny; E Weitzberg; A Rudehill; K Alving; A Sollevi
Journal:  Gut       Date:  1998-05       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.